1. Edwards L., Wanless I.R. Mechanisms of liver involvement in systemic disease. Best Pract Res Clin Gastroenterol. 2013; 27(4): 471 - 483. https://doi.org/10.1016/j.bpg.2013.08.002.

2. Ricciuto A., Kamath B.M. Liver Disease in Pediatric Inflammatory Bowel Disease. In: Mamula P., Grossman A., Baldassano R., Kelsen J., Markowitz J. (eds.). Pediatric Inflammatory Bowel Disease. Springer, Cham.; 2017, pp. 117 - 134. https://doi.org/10.1007/978-3-319-49215-5_11.

3. Goyal A., Hyams J.S., Lerer T., Leleiko N.S., Otley A.R., Griffiths A.M. et al. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease. J Pediatr Gastroenterol Nutr. 2014; 59(3): 321 - 323. https://doi.org/10.1097/MPG.0000000000000409.

4. Усольцева О.В., Сурков А.Н., Мовсисян Г.Б., Потапов А.С., Кулебина Е.А., Куликов К.А., Черников В.В. Связь воспалительных заболеваний кишечника с выраженностью поражения печени при аутоиммунной гепатобилиарной патологии: одномоментное исследование. Вопросы современной педиатрии. 2022; 21(2): 105 - 112. https://doi.org/10.15690/pf.v19i2.2407.

5. Mazzon E., Puzzolo D., Caputi A.P., Cuzzocrea S. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol Med. 2002; 8(7): 353 - 366.

6. Gizard E., Ford A.C., Bronowicki J.P., Peyrin-Biroulet L. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 40(1): 3 - 15. https://doi.org/10.1111/apt.12794.

7. Trivedi P.P., Jena G.B. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013; 201(1 - 3): 19 - 30. https://doi.org/10.1016/j.cbi.2012.12.004.

8. , Schmidt K.J., Olsen V., , Mackenroth T., Sina C. et al. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol. 2015; 27(6): 698 - 704. https://doi.org/10.1097/MEG.0000000000000350.

9. Mancina R.M., Spagnuolo R., Milano M., Brogneri S., Morrone A., Cosco C. et al. PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflamm Bowel Dis. 2016; 22(1): 134 - 140. https://doi.org/10.1097/MIB.0000000000000569.

10. Banales J.M., Huebert R.C., Karlsen T., Strazzabosco M., LaRusso N.F., Gores G.J. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019; 16(5): 269 - 281. https://doi.org/10.1038/s41575-019-0125-y.

11. Ortiz-Perez A., Donnelly B., Temple H., Tiao G., Bansal R., Mohanty S.K. Innate Immunity and Pathogenesis of Biliary Atresia. Front Immunol. 2020; 11: 329. https://doi.org/10.3389/fimmu.2020.00329.

12. Pinto C., Giordano D.M., Maroni L., Marzioni M. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt B): 1270 - 1278. https://doi.org/10.1016/j.bbadis.2017.07.024.

13. Huh C.W., Jang S.I., Lim B.J., Kim H.W., Kim J.K., Park J.S. et al. Clinicopathological features of choledocholithiasis patients with high aminotransferase levels without cholangitis: Prospective comparative study. Medicine (Baltimore). 2016; 95(42): e5176. https://doi.org/10.1097/MD.0000000000005176.

14. Тареев Е.М. (ред.). Руководство по внутренним болезням: в 10 т. Т. 5. Болезни печени и желчных путей. М.: Медицина; 1965. 724 с.

15. Fatima H., Avasthi D. Acute Severe Transaminitis as a Unique Presentation of Chronic Cholecystitis. Cureus. 2021; 13(7): e16102. https://doi.org/10.7759/cureus.16102.

16. Halvorsen F.A., Ritland S. Gallegangsokklusjon med laboratorieutfall som ved levercelleskade. Tidsskr Nor Laegeforen. 1989; 109(16): 1779 - 1781.

17. Isogai M. Proposal of the term "gallstone cholangiopancreatitis" to specify gallstone pancreatitis that needs urgent endoscopic retrograde cholangiopancreatography. World J Gastrointest Endosc. 2021; 13(10): 451 - 459. https://doi.org/10.4253/wjge.v13.i10.451.

18. Минушкин О.Н. Хронический панкреатит: некоторые аспекты патогенеза, диагностики и лечения. Consilium Medicum. 2002; 4(1): 23 - 26.

19. Abadie V., Han A.S., Jabri B., Sollid L.M. New Insights on Genes, Gluten, and Immunopathogenesis of Celiac Disease. Gastroenterology. 2024; 167(1): 4 - 22. https://doi.org/10.1053/j.gastro.2024.03.042.

20. , Araya M., Roncoroni L., Doneda L., Elli L. Dietary Gluten as a Conditioning Factor of the Gut Microbiota in Celiac Disease. Adv Nutr. 2020; 11(1): 160 - 174. https://doi.org/10.1093/advances/nmz080.

21. Rubio-Tapia A., Murray J.A. Liver involvement in celiac disease. Minerva Med. 2008; 99(6): 595 - 604.

22. , Werel P., , Orzechowska D., Wudarski M., Gietka A. Liver involvement in rheumatic diseases. Reumatologia. 2020; 58(5): 289 - 296. https://doi.org/10.5114/reum.2020.99782.

23. Wang C.R., Tsai H.W. Autoimmune liver diseases in systemic rheumatic diseases. World J Gastroenterol. 2022; 28(23): 2527 - 2545. https://doi.org/10.3748/wjg.v28.i23.2527.

24. Joshi D. Rheumatic and connective tissue disorders. Clin Liver Dis (Hoboken). 2016; 7(3): 64 - 67. https://doi.org/10.1002/cld.536.

25. Takahashi A., Abe K., Saito R., Iwadate H., Okai K., Katsushima F. et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013; 52(13): 1461 - 1465. https://doi.org/10.2169/internalmedicine.52.9458.

26. Tahernia L., Alimadadi H., Tahghighi F., Amini Z., Ziaee V. Frequency and Type of Hepatic and Gastrointestinal Involvement in Juvenile Systemic Lupus Erythematosus. Autoimmune Dis. 2017: 8097273. https://doi.org/10.1155/2017/8097273.

27. Costa D., Ceccato F., Lauretta R., Mercuri V., D'Amico T., De Vito C. et al. The prevalence of secondary neoplasms in acromegalic patients: possible preventive and/or protective role of metformin. Int J Clin Oncol. 2021; 26(6): 1015 - 1021. https://doi.org/10.1007/s10147-021-01895-y.

28. , Delgado E., Campos F. Acromegaly and associated tumours: what should gastroenterologists know? Gastroenterol Hepatol. 2017; 40(1): 41 - 47. https://doi.org/10.1016/j.gastrohep.2015.12.009.

29. Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А. и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024; 34(2): 35 - 44. https://doi.org/10.22416/1382-4376-2024-961.

30. Marengo M., Briet C., Munier M., Boursier J., Rodien P., Suteau V. Fatty Liver Disease Along Cushing Syndrome Evolution. J Clin Endocrinol Metab. 2025; 110(6): e2037 - e2044. https://doi.org/10.1210/clinem/dgae568.

31. Lonardo A., Mantovani A., Lugari S., Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. Int J Mol Sci. 2019; 20(11): 2841. https://doi.org/10.3390/ijms20112841.

32. Asfari M.M., Sarmini M.T., Baidoun F., Al-Khadra Y., Ezzaizi Y., Dasarathy S., McCullough A. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol. 2020; 7(1): e000352. https://doi.org/10.1136/bmjgast-2019-000352.

33. Arefhosseini S., Ebrahimi-Mameghani M., Najafipour F., Tutunchi H. Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones. Front Endocrinol (Lausanne). 2022; 13: 1032361. https://doi.org/10.3389/fendo.2022.1032361.

34. Piantanida E., Ippolito S., Gallo D., Masiello E., Premoli P., Cusini C. et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest. 2020; 43(7): 885 - 899. https://doi.org/10.1007/s40618-020-01208-6.

35. Yorke E. Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity. Clin Med Insights Endocrinol Diabetes. 2022; 15: 11795514221074672. https://doi.org/10.1177/11795514221074672.

36. Scappaticcio L., Longo M., Maiorino M.I., Pernice V., Caruso P., Esposito K., Bellastella G. Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid. 2021; 31(6): 884 - 894. https://doi.org/10.1089/thy.2020.0715.

37. Caraballo C., Jaimes F. Organ Dysfunction in Sepsis: An Ominous Trajectory From Infection To Death. Yale J Biol Med. 2019; 92(4): 629 - 640.

38. Chen J.W., Liu C.Y., Li S., Wu S.W., Cai C., Lu M.Q. Sepsis-associated liver injury: Mechanisms and potential therapeutic targets. World J Gastroenterol. 2024; 30(42): 4518 - 4522. https://doi.org/10.3748/wjg.v30.i42.4518.

39. Yan J., Li S., Li S. The role of the liver in sepsis. Int Rev Immunol. 2014; 33(6): 498 - 510. https://doi.org/10.3109/08830185.2014.889129.

40. Скворцов В.В., Горбач А.Н. Сепсис-индуцированная дисфункция печени: современная диагностика и стратегии лечения. Эффективная фармакотерапия. 2020; 16(15): 80 - 84. https://doi.org/10.33978/2307-3586-2020-16-15-80-84.

41. Вохминцева Л.В. Структурно-функциональные нарушения печени на фоне экспериментальной пневмонии. Бюллетень физиологии и патологии дыхания. 2007; (26): 52 - 55.

42. Minemura M., Tajiri K., Shimizu Y. Liver involvement in systemic infection. World J Hepatol. 2014; 6(9): 632 - 642. https://doi.org/10.4254/wjh.v6.i9.632.

43. Geramizadeh B., Heidari M., Shekarkhar G. Gastrointestinal Basidiobolomycosis, a Rare and Under-diagnosed Fungal Infection in Immunocompetent Hosts: A Review Article. Iran J Med Sci. 2015; 40(2): 90 - 97.

44. Fiore M., Cascella M., Bimonte S., Maraolo A.E., Gentile I., Schiavone V., Pace M.C. Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies. Infect Drug Resist. 2018; 11: 177 - 186. https://doi.org/10.2147/IDR.S152473.

45. Elsheikh R., Tien H.T., Makram A.M., Van N.T., Le T.T.B., Vasanthakumaran T., Huy N.T. Acute hepatitis of unknown origin in children: Behind the statistics. Hepatology. 2023; 77(6): 2118 - 2127. https://doi.org/10.1002/hep.32682.

46. Goyal M.K., Dhaliwal K.K., Agrawal S. "Syphilitic Hepatitis": A Comprehensive Review of Clinical Features, Diagnostic Approaches, and Management Considerations. J Clin Gastroenterol. 2024; 58(7): 635 - 639. https://doi.org/10.1097/MCG.0000000000002035.

47. Johnson R.C. Leptospira. In: Baron S. (ed.). Medical Microbiology. 4^th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 35. Available at: https://www.ncbi.nlm.nih.gov/books/NBK8451/.

48. Nadeem M., Tafader A., Markley J.D., Bajaj J.S. Liver manifestations of tick-borne diseases. Clin Liver Dis (Hoboken). 2023; 21(4): 111 - 116. https://doi.org/10.1097/CLD.0000000000000025.

49. Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am. 2008; 22(2): 341 - 360. https://doi.org/10.1016/j.idc.2007.12.011.

50. Pachner A.R., Steiner I. Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol. 2007; 6(6): 544 - 552. https://doi.org/10.1016/S1474-4422(07) 70128-X.

51. Pellegrin M., Delsol G., Auvergnat J.C., Familiades J., Faure H., Guiu M., Voigt J.J. Granulomatous hepatitis in Q fever. Hum Pathol. 1980; 11(1): 51 - 57. https://doi.org/10.1016/s0046-8177(80) 80105-5.

52. Ющук Н.Д., Венгеров Ю.Я. (ред.). Инфекционные болезни: национальное руководство. 3-е изд. М.: ГЭОТАР-Медиа; 2021. 1104 с.

53. Northup P.G., Garcia-Pagan J.C., Garcia-Tsao G., Intagliata N.M., Superina R.A., Roberts L.N. et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 73(1): 366 - 413. https://doi.org/10.1002/hep.31646.

54. Hirschfield G.M., Gill P., Neuberger J. (eds.). The Liver in Systemic Disease: A Clinician's Guide to Abnormal Liver Tests. 1^st ed. John Wiley & Sons Ltd.; 2023. 288 p.

55. Gelbmann C.M., , Wimmer M., , , Endlicher E. et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol. 2007; 102(6): 1221 - 1229. https://doi.org/10.1111/j.1572-0241.2007.01118.x.

56. Kim J.S., Wang J.H., Lemasters J.J. Mitochondrial permeability transition in rat hepatocytes after anoxia/reoxygenation: role of Ca2+-dependent mitochondrial formation of reactive oxygen species. Am J Physiol Gastrointest Liver Physiol. 2012; 302(7): G723 - 731. https://doi.org/10.1152/ajpgi.00082.2011.

57. Perry B.C., Soltys D., Toledo A.H., Toledo-Pereyra L.H. Tumor necrosis factor- in liver ischemia/reperfusion injury. J Invest Surg. 2011; 24(4): 178 - 188. https://doi.org/10.3109/08941939.2011.568594.

58. Jaeschke H., Woolbright B.L. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Rev (Orlando). 2012; 26(2): 103 - 114. https://doi.org/10.1016/j.trre.2011.10.006.

59. Wanless I.R., Liu J.J., Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995; 21(5): 1232 - 1237.

60. Wanless I.R., Huang W.Y. Vascular disorders. In: Burt A., Portmann B., Ferrell L. (eds.). MacSween's pathology of the liver. 6^th ed. Philadelphia: Churchill Livingstone Elsevier; 2012, pp. 602 - 644.

61. Kakar S., Batts K.P., Poterucha J.J., Burgart L.J. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod Pathol. 2004; 17(7): 874 - 878. https://doi.org/10.1038/modpathol.3800073.

62. Czaja A.J. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011; 56(12): 3421 - 3438. https://doi.org/10.1007/s10620-011-1769-9.

63. Bargiggia S., Maconi G., Elli M., Molteni P., Ardizzone S., Parente F. et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003; 36(5): 417 - 420. https://doi.org/10.1097/00004836-200305000-00012.

64. , Nikkonen A., Kolho K.L. Liver enzyme profiles after initiating biological treatment in children with inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2024; 79(3): 583 - 591. https://doi.org/10.1002/jpn3.12300.

65. Rojas-Feria M., Castro M., , Ampuero J., Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013; 19(42): 7327 - 7340. https://doi.org/10.3748/wjg.v19.i42.7327.

66. Chapman M.H., Thorburn D., Hirschfield G.M., Webster G.G.J., Rushbrook S.M., Alexander G. et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019; 68(8): 1356 - 1378. https://doi.org/10.1136/gutjnl-2018-317993.

67. Mendes F.D., Levy C., Enders F.B., Loftus E.V. Jr, Angulo P., Lindor K.D. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007; 102(2): 344 - 350. https://doi.org/10.1111/j.1572-0241.2006.00947.x.

68. Daniluk U., Kwiatek-Sredzinska K., Jakimiec P., Daniluk J., Czajkowska A., Lebensztejn D.M. Liver Pathology in Children with Diagnosed Inflammatory Bowel Disease-A Single Center Experience. J Clin Med. 2021; 10(22): 5359. https://doi.org/10.3390/jcm10225359.

69. Barendregt J., de Jong M., Haans J.J., van Hoek B., Hardwick J., Veenendaal R. et al. Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn's disease. Int J Colorectal Dis. 2017; 32(4): 459 - 467. https://doi.org/10.1007/s00384-016-2706-3.

70. Van Rheenen P.F., Kolho K.L., Russell R.K., Aloi M., Deganello A., Hussey S. et al. Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group. J Pediatr Gastroenterol Nutr. 2025; 80(2): 374 - 393. https://doi.org/10.1002/jpn3.12378.

71. Chandrakumar A., Loeppky R., Deneau M., El-Matary W. Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels. J Pediatr. 2019; 215: 144 - 151. e3. https://doi.org/10.1016/j.jpeds.2019.07.065.

72. Pusateri A.J., Kim S.C., Dotson J.L., Balint J.P., Potter C.J., Boyle B.M., Crandall W.V. Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015; 60(5): 592 - 597. https://doi.org/10.1097/MPG.0000000000000672.

73. Ricciuto A., Kamath B.M., Griffiths A.M. The IBD and PSC Phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018; 20(4): 16. https://doi.org/10.1007/s11894-018-0620-2.

74. Усольцева О.В., Сурков А.Н., Потапов А.С., Мовсисян Г.Б., Черников В.В. Сочетание аутоиммунной гепатобилиарной патологии с воспалительными заболеваниями кишечника у детей. Российский педиатрический журнал. 2022; 25(2): 106 - 115. https://doi.org/10.46563/1560-9561-2022-25-2-106-115.

75. Joosse M.E., Haisma S.M., Sterk M.F.M., van Munster K.N., Ponsioen C.I.J., Houwen R.H.J. et al. Disease progression in paediatric- and adult-onset sclerosing cholangitis: Results from two independent Dutch registries. Liver Int. 2019; 39(9): 1768 - 1775. https://doi.org/10.1111/liv.14159.

76. Deneau M.R., El-Matary W., Valentino P.L., Abdou R., Alqoaer K., Amin M. et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology. 2017; 66(2): 518 - 527. https://doi.org/10.1002/hep.29204.

77. Mohamed M.F.H., Elfert K., Wadhavkar N., Marino D., Farrakhan K., Beran A. et al. Choledocholithiasis Can Present with Marked Transaminases Elevation: Systematic Review and Meta-Analysis. Dig Dis Sci. 2023; 68(8): 3428 - 3435. https://doi.org/10.1007/s10620-023-07981-7.

78. Tan J.G.K., O'Sullivan J., Wijesuriya R. Incidental Intraoperatively Detected Choledocholithiasis: A General Surgeon's Approach to Management. Cureus. 2023; 15(10): e47634. https://doi.org/10.7759/cureus.47634.

79. Nathwani R.A., Kumar S.R., Reynolds T.B., Kaplowitz N. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005; 100(2): 295 - 298. https://doi.org/10.1111/j.1572-0241.2005.40793.x.

80. Блюгер А.Ф., Новицкий И.Н. Практическая гепатология. Рига: Звайгзне; 1984. 405 с.

81. Campos S., Silva N., Carvalho A. A New Paradigm in Gallstones Diseases and Marked Elevation of Transaminases: An Observational Study. Ann Hepatol. 2017; 16(2): 285 - 290. https://doi.org/10.5604/16652681.1231588.

82. Jena A., Kumar M.P., Kumar A., Birda C.L., Choudhury A., Kumar N. et al. Liver abnormalities in celiac disease and response to gluten free diet: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2023; 38(1): 11 - 22. https://doi.org/10.1111/jgh.16039.

83. , Kaukinen K., Collin P., Haapala A.M., Holm P., Laurila K. et al. Gluten-sensitive hypertransaminasemia in celiac disease: an infrequent and often subclinical finding. Am J Gastroenterol. 2011; 106(9): 1689 - 1696. https://doi.org/10.1038/ajg.2011.134.

84. Ludvigsson J.F., , , Ekbom A., Montgomery S.M. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol. 2007; 5(1): 63 - 69. e1. https://doi.org/10.1016/j.cgh.2006.09.034.

85. Yao J., Sun J., Ebrahimi F., Bergman D., Green P.H.R., Hagstr m H. et al. Long-term risk of chronic liver disease in patients with celiac disease: a nationwide population-based, sibling-controlled cohort study. Lancet Reg Health Eur. 2025; 50: 101201. https://doi.org/10.1016/j.lanepe.2024.101201.

86. Floreani A., Betterle C., Baragiotta A., Martini S., Venturi C., Basso D. et al. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis. 2002; 34(4): 258 - 261. https://doi.org/10.1016/s1590-8658(02) 80145-1.

87. Sorensen H.T., Thulstrup A.M., Blomqvist P., N rgaard B., Fonager K., Ekbom A. Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data. Gut. 1999; 44(5): 736 - 738. https://doi.org/10.1136/gut.44.5.736.

88. Reilly N.R., Lebwohl B., Hultcrantz R., Green P.H., Ludvigsson J.F. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol. 2015; 62(6): 1405 - 1411. https://doi.org/10.1016/j.jhep.2015.01.013.

89. , Glimberg I., Lebwohl B., Sharma R., Verna E.C., Green P.H.R., Ludvigsson J.F. High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta-analysis. Liver Int. 2021; 41(11): 2693 - 2702. https://doi.org/10.1111/liv.15000.

90. Kaptan K.N., , Turan E., Celiac Disease and Autoimmune Hepatitis Presenting with Fulminant Hepatic Failure: A Case Report. Erciyes Med J. 2021; 43(4): 403 - 455. Available at: https://jcpres.com/storage/upload/pdfs/EMJ-21456-CASE_REPORT-KAPTAN.pdf.

91. Van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med. 1996; 48(6): 244 - 253. https://doi.org/10.1016/0300-2977(96)00003-4.

92. Imran S., Thabah M.M., Azharudeen M., Ramesh A., Bobby Z., Negi V.S. Liver Abnormalities in Systemic Lupus Erythematosus: A Prospective Observational Study. Cureus. 2021; 13(6): e15691. https://doi.org/10.7759/cureus.15691.

93. Панова А.П., Авдеев В.Г., Краснова Т.Н., Розина Т.П., Павликова Е.П., Георгинова О.А. и др. Поражение печени у больных системной красной волчанкой. Научно-практическая ревматология. 2021; 59(2): 164 - 172. https://doi.org/10.47360/1995-4484-2021-164-172.

94. Lowe J.R., Pickup M.E., Dixon J.S., Leatham P.A., Rhind V.M., Wright V., Downie W.W. Gamma glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1978; 37(5): 428 - 431. https://doi.org/10.1136/ard.37.5.428.

95. Marino L., Jornayvaz F.R. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 21(39): 11053 - 11076. https://doi.org/10.3748/wjg.v21.i39.11053.

96. Zhang X., Wong G.L., Yip T.C., Cheung J.T.K., Tse Y.K., Hui V.W. et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. 2022; 76(5): 1409 - 1422. https://doi.org/10.1002/hep.32476.

97. Guo Y., Guo W., Chen H., Sun J., Yin Y. Mechanisms of sepsis-induced acute liver injury: a comprehensive review. Front Cell Infect Microbiol. 2025; 15: 1504223. https://doi.org/10.3389/fcimb.2025.1504223.

98. Daxboeck F., Gattringer R., Mustafa S., Bauer C., Assadian O. Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia. Clin Microbiol Infect. 2005; 11(6): 507 - 510. https://doi.org/10.1111/j.1469-0691.2005.01154.x.

99. Guo K., Ren J., Wang G., Gu G., Li G., Wu X. et al. Early Liver Dysfunction in Patients With Intra-Abdominal Infections. Medicine (Baltimore). 2015; 94(42): e1782. https://doi.org/10.1097/MD.0000000000001782.

100. Choy J., Sethi V., Mosco-Guzman J., Hoffman T., Connelly W. A Diagnosis Not to Miss: A Case of Fitz-Hugh-Curtis Syndrome. Case Rep Infect Dis. 2022: 1185314. https://doi.org/10.1155/2022/1185314.

101. Liu Y., Lan C., Qin S., Qin Z., Zhang Z., Zhang P., Cao W. Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis. Mycoses. 2022; 65(10): 906 - 917. https://doi.org/10.1111/myc.13508.

102. Kaur B., Rosenblatt R., Sundaram V. Infections in Alcoholic Hepatitis. J Clin Transl Hepatol. 2022; 10(4): 718 - 725. https://doi.org/10.14218/JCTH.2022.00024.

103. Hickey A.J., Gounder L., Moosa M.Y., Drain P.K. A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection. BMC Infect Dis. 2015; 15: 209. https://doi.org/10.1186/s12879-015-0944-6.

104. Garmpis N., Damaskos C., Garmpi A., Liakea A., Mantas D. The Unexpected Diagnosis of Hepatic Tuberculosis in an Immunocompetent Patient. Case Rep Surg. 2020: 7915084. https://doi.org/10.1155/2020/7915084.

105. Alemam A., Ata S., Shaikh D., Leuzzi B., Makker J. Syphilitic Hepatitis: A Rare Cause of Acute Liver Injury. Cureus. 2021; 13(5): e14800. https://doi.org/10.7759/cureus.14800.

106. Leptospirosis. Annual Epidemiological Reportfor 2022. Stockholm: ECDC; 2024. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/LEPT_AER_2022_Report.pdf.

107. Vine L.J., Shepherd K., Hunter J.G., Madden R., Thornton C., Ellis V. et al. Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment Pharmacol Ther. 2012; 36(1): 16 - 21. https://doi.org/10.1111/j.1365-2036.2012.05122.x.

108. , , Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation. 2003; 76(3): 536 - 539. https://doi.org/10.1097/01.TP.0000069233.13409.DF.

109. Ho J.K., Tha S.P., Coupland R., Dalal B.I., Bowie W.R., Sreenivasan G.M. et al. Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol. 2005; 19(3): 161 - 162. https://doi.org/10.1155/2005/853947.

110. Waseem N., Chen P.H. Hypoxic Hepatitis: A Review and Clinical Update. J Clin Transl Hepatol. 2016; 4(3): 263 - 268. https://doi.org/10.14218/JCTH.2016.00022.

111. Tapper E.B., Sengupta N., Bonder A. The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis. Am J Med. 2015; 128(12): 1314 - 1321. https://doi.org/10.1016/j.amjmed.2015.07.033.

112. Fuhrmann V., Kneidinger N., Herkner H., Heinz G., Nikfardjam M., Bojic A. et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med. 2009; 35(8): 1397 - 1405. https://doi.org/10.1007/s00134-009-1508-2.

113. Raurich J.M., Llompart-Pou J.A., Ferreruela M., Colomar A., Molina M., Royo C. et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth. 2011; 25(1): 50 - 56. https://doi.org/10.1007/s00540-010-1058-3.

114. Henrion J. Hypoxic hepatitis. Liver Int. 2012; 32(7): 1039 - 1052. https://doi.org/10.1111/j.1478-3231.2011.02655.x.

115. Kavoliuniene A., Vaitiekiene A., Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol. 2013; 166(3): 554 - 558. https://doi.org/10.1016/j.ijcard.2012.05.003.

116. , Candolo A.C.R., Nardelli M.J., Zitelli P.M., Mazo D.F.C., Oliveira C.P. et al. Cryptogenic chronic hepatitis: looking for an ideal diagnostic algorithm. Front Gastroenterol. 2023; 2: 1209000. https://doi.org/10.3389/fgstr.2023.1209000.

117. Fiel M.I., Schiano T.D. Systemic Disease and the Liver-Part 1: Systemic Lupus Erythematosus, Celiac Disease, Rheumatoid Arthritis, and COVID-19. Surg Pathol Clin. 2023; 16(3): 473 - 484. https://doi.org/10.1016/j.path.2023.04.003.

118. Narciso-Schiavon J.L., Schiavon L.L. To screen or not to screen? Celiac antibodies in liver diseases. World J Gastroenterol. 2017; 23(5): 776 - 791. https://doi.org/10.3748/wjg.v23.i5.776.

119. Chentoufi A.A., Serov Y.A., Alazmi M., Baba K. Immune Components of Liver Damage Associated with Connective Tissue Diseases. J Clin Transl Hepatol. 2014; 2(1): 37 - 44. https://doi.org/10.14218/JCTH.2014.00001.

120. Kojima H., Uemura M., Sakurai S., Ann T., Ishii Y., Imazu H. et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol. 2002; 37(8): 617 - 625. https://doi.org/10.1007/s005350200098.

121. Bharti A., Meena L.P. Systemic lupus erythematosus with hepatosplenic granuloma: a rare case. Case Reports Immunol. 2014: 737453. https://doi.org/10.1155/2014/737453.

122. Мишнев О.Д., Туманова У.Н., Щеголев А.И. Патология печени при сепсисе. Международный журнал прикладных и фундаментальных исследований. 2017; (8 - 2): 267 - 271. Режим доступа: https://applied-research.ru/ru/article/view?id=11798.

123. Van den Broecke A., Van Coile L., Decruyenaere A., Colpaert K., Benoit D., Van Vlierberghe H., Decruyenaere J. Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis. Ann Intensive Care. 2018; 8(1): 15. https://doi.org/10.1186/s13613-018-0356-z.

124. Wu L., Chen L., Peng L., Liu C., He S., Xie L. Clinical characteristics of Chlamydia psittaci pneumonia and predictors analysis of severe patients: a retrospective observational study. Front Med (Lausanne). 2025; 12: 1565254. https://doi.org/10.3389/fmed.2025.1565254.

125. Barros N., Rosenblatt R.E., Phipps M.M., Fomin V., Mansour M.K. Invasive fungal infections in liver diseases. Hepatol Commun. 2023; 7(9): e0216. https://doi.org/10.1097/HC9.0000000000000216.

126. Boussen I., Lisan Q., Raffoux E., Di Blasi R., Boissel N., Oksenhendler E. et al. Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. Open Forum Infect Dis. 2022; 9(4): ofac088. https://doi.org/10.1093/ofid/ofac088.

127. Lewis J.H., Patel H.R., Zimmerman H.J. The spectrum of hepatic candidiasis. Hepatology. 1982; 2(4): 479 - 487. https://doi.org/10.1002/hep.1840020415.

128. Farr RW. Leptospirosis. Clin Infect Dis. 1995; 21(1): 1 - 6. https://doi.org/10.1093/clinids/21.1.1.

129. Domingo P., , Franquet T., Gurgu M., Sancho F., Vazquez G. Acute Q fever in adult patients: report on 63 sporadic cases in an urban area. Clin Infect Dis. 1999; 29(4): 874 - 879. https://doi.org/10.1086/520452.

130. Petrova M., Muhtarova M., Nikolova M., Magaev S., Taskov H., Nikolovska D., Krastev Z. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients. World J Gastroenterol. 2006; 12(35): 5711 - 5716. https://doi.org/10.3748/wjg.v12.i35.5711.

131. Petrova M., Kamburov V. Epstein-Barr virus: silent companion or causative agent of chronic liver disease? World J Gastroenterol. 2010; 16(33): 4130 - 4134. https://doi.org/10.3748/wjg.v16.i33.4130.

132. Drebber U., Kasper H.U., Krupacz J., Haferkamp K., Kern M.A., Steffen H.M. et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol. 2006; 44(5): 879 - 885. https://doi.org/10.1016/j.jhep.2006.02.006.

133. Razonable R.R. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008; 14(31): 4849 - 4860. https://doi.org/10.3748/wjg.14.4849.

134. Gallegos-Orozco J.F., Rakela-Br dner J. Hepatitis viruses: not always what it seems to be. Rev Med Chil. 2010; 138(10): 1302 - 1311.

135. Dits H., Frans E., Wilmer A., Van Ranst M., Fevery J., Bobbaers H. Varicella-zoster virus infection associated with acute liver failure. Clin Infect Dis. 1998; 27(1): 209 - 210. https://doi.org/10.1086/514613.

136. Hashida T., Komura E., Yoshida M., Otsuka T., Hibi S., Imashuku S. et al. Hepatitis in association with human herpesvirus-7 infection. Pediatrics. 1995; 96(4 Pt 1): 783 - 785.

137. Tameda Y., Kosaka Y., Shiraki K., Ohashi Y., Hamada M., Miyazaki M. et al. Hepatitis in an adult with rubella. Intern Med. 1993; 32(7): 580 - 583. https://doi.org/10.2169/internalmedicine.32.580.

138. Arai M., Wada N., Maruyama K., Nomiyama T., Tanaka S., Okazaki I. Acute hepatitis in an adult with acquired rubella infection. J Gastroenterol. 1995; 30(4): 539 - 542. https://doi.org/10.1007/BF02347575.

139. Sezai Y., Nagashima T. Significance of LDH isozyme pattern in rubella. Nihon Hifuka Gakkai Zasshi. 1989; 99(7): 811 - 817.

140. Kawai K., Kawai A. Increased serum lactate dehydrogenase and changes in its isozymes pattern correlated to the atypical lymphocytes in adult rubella. Nihon Naika Gakkai Zasshi. 1989; 78(4): 500 - 505. https://doi.org/10.2169/naika.78.500.

141. Dinh A., Fleuret V., Hanslik T. Liver involvement in adults with measles. Int J Infect Dis. 2013; 17(12): e1243 - 1244. https://doi.org/10.1016/j.ijid.2013.06.014.

142. Rothenberg M., Cheung R., Ahmed A. Adenovirus-induced acute liver failure. Dig Dis Sci. 2009; 54(2): 218 - 221. https://doi.org/10.1007/s10620-008-0628-9.

143. Birrer R., Takuda Y., Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med. 2007; 46(14): 1063 - 1070. https://doi.org/10.2169/internalmedicine.46.0059.

144. Myers R.P., Cerini R., Sayegh R., Moreau R., Degott C., Lebrec D., Lee S.S. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology. 2003; 37(2): 393 - 400. https://doi.org/10.1053/jhep.2003.50062.

145. Ивашкин В.Т. Пропедевтика внутренних болезней. 2-е изд. М.: ГЭОТАР-Медиа; 2023. 936 с.

146. Fuhrmann V, Drolz A, Kneidinger N, Schenk P. Hyperammonemia in patients with hypoxic hepatitis. Gut. 2009; 58: P0450.

147. Trilok G., Qing Y.C., Li-Jun X. Hypoxic hepatitis: a challenging diagnosis. Hepatol Int. 2012; 6(4): 663 - 669. https://doi.org/10.1007/s12072-011-9336-1.

148. , Drolz A., Michl B., Schellongowski P., Bojic A., Nikfardjam M. et al. Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. Hepatology. 2012; 56(6): 2297 - 2304. https://doi.org/10.1002/hep.25896.

149. Runyon B.A. Cardiac ascites: a characterization. J Clin Gastroenterol. 1988; 10(4): 410 - 412. https://doi.org/10.1097/00004836-198808000-00013.

150. Ponsioen C.Y., Assis D.N., Boberg K.M., Bowlus C.L., Deneau M., Thorburn D. et al. Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology. 2021; 161(6): 1764 - 1775. e5. https://doi.org/10.1053/j.gastro.2021.07.046.

151. Van Rheenen P.F. Managing abnormal liver tests in children with inflammatory bowel disease. Curr Opin Pediatr. 2021; 33(5): 521 - 529. https://doi.org/10.1097/MOP.0000000000001045.

152. Gordon H., Burisch J., Ellul P., Karmiris K., Katsanos K., Allocca M. et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024; 18(1): 1 - 37. https://doi.org/10.1093/ecco-jcc/jjad108.

153. Hensel K.O., Kyrana E., Hadzic N., Mann J., Mieli-Vergani G., Gasparetto M. et al. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome. J Pediatr. 2021; 238: 50 - 56. e3. https://doi.org/10.1016/j.jpeds.2021.07.047.

154. Shamberg L., Vaziri H. Hepatotoxicity of Inflammatory Bowel Disease Medications. J Clin Gastroenterol. 2018; 52(8): 674 - 684. https://doi.org/10.1097/MCG.0000000000001084.

155. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available at:https://www.ncbi.nlm.nih.gov/books/NBK547852/.

156. Wiegard C., Schramm C., Lohse A.W. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis. 2009; 29(3): 254 - 261. https://doi.org/10.1055/s-0029-1233532.

157. Jujaray D., Juan L.Z., Shrestha S., Ballgobin A. Pattern and Significance of Asymptomatic Elevation of Liver Enzymes in Mycoplasma Pneumonia in Children. Clin Pediatr (Phila). 2018; 57(1): 57 - 61. https://doi.org/10.1177/0009922816688737.

158. Chong V.H., Lim K.S. Hepatobiliary tuberculosis. Singapore Med J. 2010; 51(9): 744 - 751.

159. Haddadin R., Aboujaoude C., Trad G. Congestive Hepatopathy: A Review of the Literature. Cureus. 2024; 16(4): e58766. https://doi.org/10.7759/cureus.58766.

160. Ford R.M., Book W., Spivey J.R. Liver disease related to the heart. Transplant Rev (Orlando). 2015; 29(1): 33 - 37. https://doi.org/10.1016/j.trre.2014.11.003.

161. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.В. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31(6): 56 - 102. Режим доступа: https://www.gastro-j.ru/jour/article/view/621.

162. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(4): 104 - 140. https://doi.org/10.22416/1382-4376-2022-32-4-104-140.

163. Bhatia V., Bavdekar A., Yachha S.K. Management of acute liver failure in infants and children: consensus statement of the pediatric gastroenterology chapter, Indian academy of pediatrics. Indian Pediatr. 2013; 50(5): 477 - 482. https://doi.org/10.1007/s13312-013-0147-4.

164. Di Giorgio A., Bartolini E., Calvo P.L., Cananzi M., Cirillo F., Della Corte C. et al. Diagnostic Approach to Acute Liver Failure in Children: A Position Paper by the SIGENP Liver Disease Working Group. Dig Liver Dis. 2021; 53(5): 545 - 557. https://doi.org/10.1016/j.dld.2021.03.004.

165. Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J. et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020; 72(2): 671 - 722. https://doi.org/10.1002/hep.31065.

166. Newsome P.N., Cramb R., Davison S.M., Dillon J.F., Foulerton M., Godfrey E.M. et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018; 67(1): 6 - 19. https://doi.org/10.1136/gutjnl-2017-314924.

167. Wang X., Wang G., Shang J., Pan H., Zhang X.A., Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res. 2019; 47(8): 3534 - 3549. https://doi.org/10.1177/0300060519864800.

168. , Gerner P., Enninger A., , Radke M. Inflammatory Bowel Disease in Childhood and Adolescence. Dtsch Arztebl Int. 2017; 114(19): 331 - 338. https://doi.org/10.3238/arztebl.2017.0331.

169. Oliveira S.B., Monteiro I.M. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017; 357: j2083. https://doi.org/10.1136/bmj.j2083.

170. Yamamoto-Furusho J.K., , Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010; 9(4): 397 - 401.

171. Valentino P.L., Feldman B.M., Walters T.D., Griffiths A.M., Ling S.C., Pullenayegum E.M., Kamath B.M. Abnormal Liver Biochemistry Is Common in Pediatric Inflammatory Bowel Disease: Prevalence and Associations. Inflamm Bowel Dis. 2015; 21(12): 2848 - 2856. https://doi.org/10.1097/MIB.0000000000000558.

172. Tetangco E.P., Shah N., Arshad H.M., Raddawi H. Markedly Elevated Liver Enzymes in Choledocholithiasis in the absence of Hepatocellular Disease: Case Series and Literature Review. J Investig Med High Impact Case Rep. 2016; 4(2): 2324709616651092. https://doi.org/10.1177/2324709616651092.

173. Абдулганиева Д.И., Алексеева О.П., Ачкасов С.И., Бакулин И.Г., Барышева О.Ю., Белоусова Е.А. и др. Язвенный колит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/193_2.

174. Абдулганиева Д.И., Абдулхаков Р.А., Адамян Л.В., Алексеева О.П., Алексеенко С.А., Александров Т.Л. и др. Болезнь Крона: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/176_2.

175. Scapaticci S., Venanzi A., Chiarelli F., Giannini C. MAFLD and Celiac Disease in Children. Int J Mol Sci. 2023; 24(2): 1764. https://doi.org/10.3390/ijms24021764.

176. Valvano M., Longo S., Stefanelli G., Frieri G., Viscido A., Latella G. Celiac Disease, Gluten-Free Diet, and Metabolic and Liver Disorders. Nutrients. 2020; 12(4): 940. https://doi.org/10.3390/nu12040940.

177. Seidita A., Latteri F., Pistone M., Giuliano A., Bertoncello L., Cavallo G. et al. Celiac Disease and Liver Damage: The Gut-Liver Axis Strikes Back (Again)? A Retrospective Analysis in the Light of a Literature Review. Nutrients. 2024; 17(1): 85. https://doi.org/10.3390/nu17010085.

178. Donnan P.T., McLernon D., Dillon J.F., Ryder S., Roderick P., Sullivan F., Rosenberg W. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess. 2009; 13(25): 1 - 134. https://doi.org/10.3310/hta13250.

179. Runde J., Azzam R.K. Hepatobiliary Manifestations in Systemic Disease. Pediatr Ann. 2018; 47(11): e458 - e464. https://doi.org/10.3928/19382359-20181023-01.

180. Mannion R., Fitzpatrick E. Systemic Complications Secondary to Chronic Liver Disease. Indian J Pediatr. 2024; 91(3): 286 - 293. https://doi.org/10.1007/s12098-023-04694-7.

181. Kawada P.S., Bruce A., Massicotte P., Bauman M., Yap J. Coagulopathy in Children With Liver Disease. J Pediatr Gastroenterol Nutr. 2017; 65(6): 603 - 607. https://doi.org/10.1097/MPG.0000000000001721.

182. D'Agostino D., Diaz S., Sanchez M.C., Boldrini G. Management and prognosis of acute liver failure in children. Curr Gastroenterol Rep. 2012; 14(3): 262 - 269. https://doi.org/10.1007/s11894-012-0260-x.

183. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Тихонов И.Н., Федосьина Е.А., Павлов Ч.С. Алгоритмы диагностики и лечения в гепатологии. М.: МЕДпресс-информ; 2016. 176 с.

184. Ben-Tov A., Achler T., Fayngor R., Shamir R., Supino L., Weintraub Y. et al. Endomysial antibodies or anti-tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease. J Pediatr Gastroenterol Nutr. 2025; 80(1): 147 - 150. https://doi.org/10.1002/jpn3.12383.

185. Pacheco M.C., Fink S.L., Lee D., Dickerson J. Tissue transglutaminase immunoglobulin A exceeds endomysial antibody in specificity of celiac diagnosis at 10 times the upper limit of normal. J Pediatr Gastroenterol Nutr. 2024; 79(6): 1164 - 1171. https://doi.org/10.1002/jpn3.12382.

186. Yodoshi T., Orkin S., Arce-Clachar A.C., Bramlage K., Xanthakos S.A., Valentino P.L., Mouzaki M. Alternative Etiologies of Liver Disease in Children With Suspected NAFLD. Pediatrics. 2021; 147(4): e2020009829. https://doi.org/10.1542/peds.2020-009829.

187. Vecchi M., Folli C., Donato M.F., Formenti S., Arosio E., de Franchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol. 2003; 38(1): 50 - 54.

188. Villalta D., Crovatto M., Stella S., Tonutti E., Tozzoli R., Bizzaro N. False positive reactions for IgA and IgG anti-tissue transglutaminase antibodies in liver cirrhosis are common and method-dependent. Clin Chim Acta. 2005; 356(1 - 2): 102 - 109. https://doi.org/10.1016/j.cccn.2005.01.015.

189. Nguyen D., Alsaati F., Deitrick J., Azhar K., Sbar E. Rhabdomyolysis secondary to systemic lupus erythematosus. Auto Immun Highlights. 2018; 9(1): 5. https://doi.org/10.1007/s13317-018-0105-1.

190. Cojocaru M., Cojocaru I.M., Silosi I., Vrabie C.D. Liver involvement in patients with systemic autoimmune diseases. Maedica (Bucur). 2013; 8(4): 394 - 397.

191. Botros M., Sikaris K.A. The de ritis ratio: the test of time. Clin Biochem Rev. 2013; 34(3): 117 - 130.

192. Al-Twaijri W.A., Al-Saif S.A., Al-Fehaid G.I., Al-Qirnas M.Q., Masuadi E.M. Elevated level of creatine phosphokinase in newborn: Clinical significance and association with congenital muscle diseases. Neurosciences (Riyadh). 2022; 27(4): 263 - 269. https://doi.org/10.17712/nsj.2022.4.20220051.

193. Trevisani V.F.M., Pinheiro A.C., de Magalh es Souza Fialho S.C., Fernandes M.L.M.S., Pugliesi A. et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sj gren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic). Adv Rheumatol. 2022; 62(1): 35. https://doi.org/10.1186/s42358-022-00267-y.

194. Deng X., Li J., Hou S., Ci B., Liu B., Xu K. Prevalence and impact of Sj gren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis. Ann Hepatol. 2022; 27(6): 100746. https://doi.org/10.1016/j.aohep.2022.100746.

195. Kim K.W., Sung J.J., Tchah H., Ryoo E., Cho H.K., Sun Y.H. et al. Hepatitis associated with Mycoplasma pneumoniae infection in Korean children: a prospective study. Korean J Pediatr. 2015; 58(6): 211 - 217. https://doi.org/10.3345/kjp.2015.58.6.211.

196. Garland J.S., Werlin S.L., Rice T.B. Ischemic hepatitis in children: diagnosis and clinical course. Crit Care Med. 1988; 16(12): 1209 - 1212. https://doi.org/10.1097/00003246-198812000-00006.

197. , Hija R.A.E., Qi X., Jenssen C., Mutze S., et al. Portal Hypertension - Noninvasive Multiparametric Ultrasound-Based Criteria and Measurements. Portal Hypertens Cirrhosis. 2025; 4(1): 44 - 65. https://doi.org/10.1002/poh2.70002.

198. Grimaldi C., de Ville de Goyet J., Nobili V. Portal hypertension in children. Clin Res Hepatol Gastroenterol. 2012; 36(3): 260 - 261. https://doi.org/10.1016/j.clinre.2012.03.016.

199. Ивашкин В.Т., Драпкина О.М., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Винницкая Е.В. и др. Цирроз и фиброз печени: клинические рекомендации. М.; 2025. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/715_2.

200. Ling S.C. Advances in the evaluation and management of children with portal hypertension. Semin Liver Dis. 2012; 32(4): 288 - 297. https://doi.org/10.1055/s-0032-1329897.

201. Li M.M., Sun F., Huai M.X., Qu C.Y., Shen F., Zhang Y., Xu L.M. Endoscopic variceal ligation combined with sclerotherapy for management of gastroesophageal variceal bleeding in pediatric patients: a single-center retrospective study. Front Pediatr. 2024; 12: 1325419. https://doi.org/10.3389/fped.2024.1325419.

202. Alkhasov A., Komina E., Ratnikov S., Saveleva M., Romanova E., Gusev A. et al. Surgical Treatment of Portal Hypertension in Children. J Laparoendosc Adv Surg Tech A. 2023; 33(12): 1231 - 1235. https://doi.org/10.1089/lap.2022.0404.

203. Venkatesh S.K., Welle C.L., Miller F.H., Jhaveri K., Ringe K.I., Eaton J.E. et al. Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. Eur Radiol. 2022; 32(2): 923 - 937. https://doi.org/10.1007/s00330-021-08147-7.

204. Anupindi S.A., Chauvin N.A., Khwaja A., Biko D.M. Magnetic resonance imaging of pancreaticobiliary diseases in children: from technique to practice. Pediatr Radiol. 2016; 46(6): 778 - 790. https://doi.org/10.1007/s00247-016-3608-9.

205. Venkatesh S.K., Welle C.L., Miller F.H., Jhaveri K., Ringe K.I., Eaton J.E. et al. Correction to: Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. Eur Radiol. 2022; 32(4): 2860. https://doi.org/10.1007/s00330-021-08333-7.

206. Rofsky N.M., Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR. 1995; 16(1): 16 - 33. https://doi.org/10.1016/0887-2171(95) 90012-8.

207. Wang G., Zhu S., Li X. Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors. Oncol Lett. 2019; 17(1): 1184 - 1188. https://doi.org/10.3892/ol.2018.9690.

208. Fischer H.P., Zhou H. Leberparenchymknoten bei pathologischer hepatischer Vaskularisation/Perfusion. Pathologe. 2006; 27(4): 273 - 283. https://doi.org/10.1007/s00292-006-0839-9.

209. Ilyas S.I., Gores G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec; 145(6): 1215 - 1229. https://doi.org/10.1053/j.gastro.2013.10.013.

210. De Padua V Alves V., Dillman J.R., Somasundaram E., Taylor Z.P., Brady S.L., Zhang B., Trout A.T. Computed tomography-based measurements of normative liver and spleen volumes in children. Pediatr Radiol. 2023; 53(3): 378 - 386. https://doi.org/10.1007/s00247-022-05551-z.

211. Park S.J., Kim J.D., Seo Y.S., Park B.J., Kim M.J., Um S.H. et al. Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis. World J Gastroenterol. 2013; 19(16): 2543 - 2549. https://doi.org/10.3748/wjg.v19.i16.2543.

212. Novacek G., Miehsler W., Wrba F., Ferenci P., Penner E., Vogelsang H. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol. 1999; 11(3): 283 - 288. https://doi.org/10.1097/00042737-199903000-00012.

213. Wafa B., Faten H., Mouna E., Fatma M., Mohamed A. Hyperthyroidism and hepatic dysfunction: Report of 17 cases. JGH Open. 2020; 4(5): 876 - 879. https://doi.org/10.1002/jgh3.12337.

214. Rabbani T., Bartlett J.M.A., Mittal N. Liver Biopsy in Children. Indian Pediatr. 2020; 57(8): 734 - 740.

215. , Baumann U., Dhawan A., Durmaz O., Fischler B., Hadzic N. et al. Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2015; 60(3): 408 - 420. https://doi.org/10.1097/MPG.0000000000000632.

216. Баранов А.А., Намазова-Баранова Л.С., Разумовский А.Ю., Хавкин А.И., Аверкина Н.А., Аксельров М.А. и др. Болезнь Крона: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/682_2.

217. Дехнич А.В., Зайцев А.А., Козлов Р.С., Лещенко И.В., Рачина С.А., Руднов В.А. и др. Внебольничная пневмония у взрослых: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/654_2.

218. Балашова Е.Н., Вайнштейн Н.П., Васильев В.В., Володин Н.Н., Дегтярев Д.Н., Дегтярева М.В. и др. Врожденная цитомегаловирусная инфекция: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/260_2.

219. Дедов И.И., Мельниченко Г.А., Фадеев В.В., Моргунова Т.Б. Гипотиреоз: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/531_4.

220. Ревишвили А.Ш., Ивашкин В.Т., Гуляев А.А., Жаркова М.С., Королев М.П., Лапина Т.Л. и др. Желчнокаменная болезнь: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/877_1.

221. Баранов А.А., Намазова-Баранова Л.С., Аверкина Н.А., Апханова Т.В., Вишнева Е.А., Волынец Г.В. и др. Желчнокаменная болезнь: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/580_3.

222. Чуланов В.П., Горелов А.В., Малявин А.Г., Зайцев А.А., Малеев В.В., Арсланова Л.В. и др. Острые респираторные вирусные инфекции (ОРВИ) у взрослых: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/724_1.

223. Баранов А.А., Намазова-Баранова Л.С., Лобзин Ю.В., Таточенко В.К., Усков А.Н., Куличенко Т.В. и др. Острая респираторная вирусная инфекция (ОРВИ): клинические рекомендации. М.; 2022. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/25_2.

224. Затевахин И.И., Ревишвили А.Ш., Багненко С.Ф., Полушин Ю.С., Майстренко Н.А., Хатьков И.Е. и др. Острый панкреатит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/903_1.

225. Баранов А.А., Козлов Р.С., Намазова-Баранова Л.С., Андреева И.В., Бакрадзе М.Д., Вишнева Е.А. и др. Пневмония (внебольничная): клинические рекомендации. М.; 2022. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/714_1.

226. Насонов Е.Л., Лила А.М., Каратеев Д.Е., Мазуров В.И., Амирджанова В.Н., Белов Б.С. и др. Ревматоидный артрит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/250_3.

227. Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2-го типа у взрослых: клинические рекомендации. М.; 2022. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/290_2.

228. Петеркова В.А., Безлепкина О.Б., Лаптев Д.Н., Еремина И.А., Сечко Е.А., Алимова И.Л. и др. Сахарный диабет 2-го типа у детей: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/622_5.

229. Александрович Ю.С., Балашова Е.Н., Боронина И.В., Завьялова А.Н., Золотарева Л.С., Иванов Д.О. и др. Сепсис новорожденных: клинические рекомендации. М.; 2025. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/912_1.

230. Багненко С.Ф., Горобец Е.С., Гусаров В.Г., Дехнич А.В., Дибиров М.Д., Ершова О.Н. и др. Сепсис (у взрослых): клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/898_1.

231. Алексеева Е.И., Дворяковская Т.М., Шилькрот И.Ю., Костик М.М., Никишина И.П., Ушакова С.А. и др. Системная красная волчанка: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/606_3.

232. Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С., Григорян О.Р., Дедов И.И., Мельниченко Г.А. и др. Синдром поликистозных яичников: клинические рекомендации. М.; 2025. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/910_1.

233. Кубанов А.А., Соколовский Е.В., Красносельских Т.В., Катунин Г.Л., Плахова К.И., Мавлютова Г.И. и др. Сифилис: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/197_2.

234. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Свириденко Н.Ю., Платонова Н.М. и др. Тиреотоксикоз с диффузным зобом (болезнь Грейвса), узловым/многоузловым зобом: клинические рекомендации. М.; 2025. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/270_2.

235. Васильева И.А., Абрамченко А.В., Андронов С.А., Баласанянц Г.С., Батыров Ф.А., Богородская Е.М. и др. Туберкулез у взрослых: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/16_3.

236. Аксенова В.А., Барышникова Л.А., Бармина Н.А., Баронова О.Д., Васильева И.А., Довгалюк И.Ф. и др. Туберкулез у детей: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/507_3.

237. Кубанов А.А., Серов В.Н., Рахматулина М.Р., Аполихина И.А., Гомберг М.А., Горбунова Е.А. и др. Хламидийная инфекция: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/194_2.

238. Ревишвили А.Ш., Ивашкин В.Т., Гуляев А.А., Жаркова М.С., Королев М.П., Лапина Т.Л. и др. Холецистит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/819_1.

239. Алексеенко С.А., Анищенко М.А., Багненко С.Ф., Бордин Д.С., Быков М.И., Будзинский С.А. и др. Хронический панкреатит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/273_5.

240. Авдеева М.Г., Городин В.Н., Прокопенко Е.И., Шахгильдян В.И., Шипулина О.Ю., Эсауленко Е.В. Цитомегаловирусная болезнь (ЦМВБ) у взрослых: клинические рекомендации. М.; 2022. Режим доступа: https://edu.nmrc.ru/wp-content/uploads/2022/04/kr_cmv.pdf.

241. Баранов А.А., Намазова-Баранова Л.С., Разумовский А.Ю., Хавкин А.И., Аверкина Н.А., Аксельров М.А. и др. Язвенный колит: клинические рекомендации. М.; 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/391_3.

242. Орадовская И.В., Викулов Г.Х., Колобухина Л.В., Малышев Н.А., Антипят Н.А. Герпесвирусные инфекции у взрослых жителей г. Москвы: заболеваемость, распространенность, нозологические формы и алгоритм ведения. Инфекционные болезни. 2022; 20(4): 125 - 142. Режим доступа: https://www.phdynasty.ru/katalog/zhurnaly/infektsionnye-bolezni/2022/tom-20-nomer-4/75337.

243. Рославцева Е.А., Дмитриева Ю.А., Захарова И.Н., Боровик Т.Э., Потапов А.С., Сурков А.Н. и др. Целиакия у детей: проект клинических рекомендаций. Экспериментальная и клиническая гастроэнтерология. 2021; (4): 199 - 227. https://doi.org/10.31146/1682-8658-ecg-188-4-199-227.

244. Barone M., Iannone A., Cristofori F., Dargenio V.N., Indrio F., Verduci E. et al. Risk of obesity during a gluten-free diet in pediatric and adult patients with celiac disease: a systematic review with meta-analysis. Nutr Rev. 2023; 81(3): 252 - 266. https://doi.org/10.1093/nutrit/nuac052.

245. Zhao X.D., Ye J., Sun Y.K., Liang J.F., Hu L., Chang A.C. et al. Hypoxic hepatitis in children after cardiac surgery. Hepatobiliary Pancreat Dis Int. 2023; 22(2): 205 - 209. https://doi.org/10.1016/j.hbpd.2022.09.012.

246. Wendon J., Cordoba J., Dhawan A., Larsen F.S., Manns M., Samuel D. et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017; 66(5): 1047 - 1081. https://doi.org/10.1016/j.jhep.2016.12.003.

247. Patel N., Sharma B., Samant H. Cryptogenic Cirrhosis. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK534228.

248. Mercado-Irizarry A., Torres E.A. Cryptogenic cirrhosis: Current knowledge and future directions. Clin Liver Dis (Hoboken). 2016; 7(4): 69 - 72. https://doi.org/10.1002/cld.539.

249. Rose PC, Cotton MF, Otwombe K, Innes S, Nel ED. Liver transient elastography values in healthy South African children. BMC Pediatr. 2023 Jul 13; 23(1): 355. doi: 10.1186/s12887-023-04170-3.

250. Brunnert L, Puasa ID, Garten A, Penke M, Gaul S, Grafe N, Karlas T, Kiess W, Flemming G, Vogel M. Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage. Front Endocrinol (Lausanne). 2022 Sep 27; 13: 1030809. doi: 10.3389/fendo.2022.1030809.

251. Сурков А.Н., Намазова-Баранова Л.С., Вашакмадзе Н.Д., Геворкян А.К., Томилова А.Ю., Потапов А.С., Сурков О.И., Кузенкова Л.М., Баранов А.А. Транзиентная эластография - неинвазивный метод диагностики стадий фиброза печени у детей с редкими болезнями. Современные технологии в медицине. 2016; 8(3): 56 - 63.

252. Кулебина Е.А., Сурков А.Н., Куликов К.А., Потапов А.С., Бессонов Е.Е. Валидация показателей транзиентной эластографии для оценки стадии фиброза печени у детей. Лечащий врач. 2020; 8: 57 - 60.